2-フェニル-1,3-インダンジオン

Phenindione

HCID 4760

基本情報

CAS
83-12-5
標準SMILES
O=C1c2ccccc2C(=O)C1c1ccccc1
InChIKey
NFBAXHOPROOJAW-UHFFFAOYSA-N
分子式
C15H10O2
平均分子量
222.24 g/mol
単同位体質量
222.06807956

概要

Phenindione is a beta-diketone and an aromatic ketone. It has a role as an anticoagulant. It derives from a hydride of an indane.

名称と識別子

優先名称
Phenindione
IUPAC
2-phenylindene-1,3-dione
現地名
2-フェニル-1,3-インダンジオン
英語名
2-Phenyl-1,3-indandione
分子式
C15H10O2
分子量
222.24

名称と別名

phenindione83-12-52-Phenyl-1,3-indandione2-Phenyl-1H-indene-1,3(2H)-dioneRectadioneDaniloneDindevanHedulinDiophindaneAthrombonFenhydrenIndon
名称をさらに表示
2-フェニル-1,3-インダンジオンフェニリンインデマジンデバン2-フェニル-2,3-ジヒドロ-1H-インデン-1,3-ジオンダニロンレクタジオン2-フェニル-1H-インデン-1,3(2H)-ジオン2-フェニルインダン-1,3-ジオンピンジオン2-フェニル-2H-インデン-1,3-ジオンアトロムボンヘズリンジアジランジネバルビンダンジオフィンダンフェニンジオンフェンヒドレンPIDIndionMTA21H-Indene-1,3(2H)-dione, 2-phenyl-BindanIndema
PhenylindanedionePhenylindioneDanedionDiadilanEmandionePhenhydrenPhenillinTheradione

データベース識別子

CAS
83-12-5
PubChem CID
4760
DTXSID
DTXSID5023453
ChEMBL
CHEMBL711
ChEBI
CHEBI:8066
UNII
5M7Y6274ZE
EC Number
201-454-4
Nikkaji
J166.097G

物性

構造計算による物性

XLogP
2.9
極性表面積
34.1 Ų
水素結合供与体数
0
水素結合受容体数
2
回転可能結合数
1
重原子数
17

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
pH4.5 IN SATURATED SOLN @ 25 °C
SpringerMaterials PropertiesChemical shift
LogP2.6
OdorALMOST ODORLESS
Color/Form · 2 件

LEAFLETS FROM ALCOHOL

CREAMY WHITE TO PALE YELLOW CRYSTALS OR CRYSTALLINE POWDER

物理化学的性質

融点
144 · 144-148 °C(lit.)
沸点
243.3 °C · 243.3 °C (0.3 mmHg)
比重(密度)
1.1404 · 1.1404 (rough estimate)
屈折率
1.66 · 1.6600 (estimate)
闪点
208 °C · 208 °C
貯蔵温度
Inert atmosphere,Room Temperature

化学的性質

化学的特性light yellow fluffy fine flakes

安全と法規制

GHS分類

GHS Classification · 4 件

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P261, P264, P270, P272, P280, P301+P316, P302+P352, P321, P330, P333+P317, P362+P364, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 43 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 3 (100%)

毒性情報

Treatment · 1 件

The primary antidote to phenindione poisoning is immediate administration of vitamin K1 (initially slow intravenous injections of 10-25 mg repeated all 3-6 hours until normalisation of the prothrombin time; then 10 mg orally four times daily as a "maintenance dose"). It is an extremely effective antidote, provided the poisoning is caught before too much damage has been done to the victim's circulatory system. At high doses phenindione can affect the body for many months, and the antidote must be administered regularly for a long period of time. (L1257)

Interactions · 5 件

HALOPERIDOL WAS FOUND TO REDUCE PROTHROMBIN TIME NORMALLY PRODUCED BY PHENINDIONE.

ACTIVITY OF...INDANDIONE ANTICOAGULANT PHENINDIONE HAVE ALSO BEEN ENHANCED BY C-17-ALKYLATED ANDROGENS.

CORTICOTROPIN & ADRENOCORTICOSTEROIDS HAVE BEEN REPORTED TO CAUSE SEVERE HEMORRHAGE WHEN GIVEN WITH ORAL ANTICOAGULANTS... /ANTICOAGULANTS/

ANTIPYRINE (IN VIVO) & SULFINPYRAZONE (IN VITRO) HAVE BEEN REPORTED TO INTERACT WITH WARFARIN & SHOULD BE USED CAUTIOUSLY IN PT RECEIVING ANTICOAGULANTS. /ANTICOAGULANTS/

For more Interactions (Complete) data for PHENINDIONE (12 total), please visit the HSDB record page.

Health EffectsPhenindione is an anticoagulant and may cause internal bleeding, leading to shock, loss of consciousness, and eventually death. (L1257)
Exposure RoutesIngestion (L1817) ; dermal (L1817). Absorbed slowly from the gastrointestinal tract.
Toxicity Summary · 1 件

Phenindione inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Depression of three of the four vitamin K-dependent coagulation factors (factors II, VII, and X) results in decresed prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots. (A308)

Signs and SymptomsPhenindione may cause bleeding complications. (L1257)

安全データ

wgk
3
rtecs
NK6125000
ridadr
UN 2811 6.1/PG 3
hs_code
2914.39.9000
risk_code
25-43
hazard_code
T

化学と産業

薬理情報

ATC Code · 2 件

B - Blood and blood forming organs

QB - Blood and blood forming organs

Protein Binding88%
Pharmacodynamics · 1 件

Phenindione thins the blood by antagonizing vitamin K which is required for the production of clotting factors in the liver. Anticoagulants such as Phenindione have no direct effect on an established thrombus, nor do they reverse ischemic tissue damage (damage caused by an inadequate blood supply to an organ or part of the body). However, once a thrombus has occurred, the goal of anticoagulant treatment is to prevent further extension of the formed clot and prevent secondary thromboembolic complications which may result in serious and possibly fatal sequelae. Phenindione has actions similar to warfarin, but it is now rarely employed because of its higer incidence of severe adverse effects.

Mechanism of Action · 3 件

Phenindione inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Depression of three of the four vitamin K-dependent coagulation factors (factors II, VII, and X) results in decreased prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots.

.../ANTICOAGULANTS/ BLOCK HEPATIC FORMATION OF FACTORS II, VII, IX, & X BY COMPETITIVELY INHIBITING ACTION OF VITAMIN K. ... COUMARIN ANTICOAGULANTS MAY ALSO AFFECT TRANSPORT OF VITAMIN K TO ITS SITE OF ACTION. /ANTICOAGULANTS/

ORAL ANTICOAGULANTS HAVE ONLY ONE MAJOR PHARMACOLOGICAL EFFECT--INHIBITION OF BLOOD-CLOTTING MECHANISMS BY INTERFERING WITH HEPATIC SYNTH OF VITAMIN K-DEPENDENT CLOTTING FACTORS. ...EXERT THEIR INITIAL EFFECT IN VIVO ONLY AFTER LATENT PERIOD... /ORAL ANTICOAGULANTS/

Biological Half-Life5-10 hours
Metabolism/Metabolites · 2 件

Hepatic.

Hepatic. Half Life: 5-10 hours

用途と製造

Uses · 2 件

MEDICATION

Phenindione is an anticoagulant drug derived from coumarin. (L1262) For the treatment of pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, mural thrombosis, and thrombophili. Also used for anticoagulant prophylaxis.

Methods of ManufacturingBY HEATING PHTHALIDE WITH BENZALDEHYDE AND SODIUM ETHYLATE SOLN: DIECKMANN, BER 47, 1439 (1914).
Formulations/Preparations...IS AVAIL FOR ORAL USE IN 20- & 50-MG TABLETS.
Use ClassificationPharmaceuticals
応用分野 · 2 件

説明Phenindione is an anticoagulant and vitamin K antagonist. It inhibits the reduction of vitamin K1 epoxide to vitamin K1 by vitamin K1 epoxide reductase in rat liver homogenates in a concentration-dependent manner. In vivo, phenindione (500 mg/kg) inhibits prothrombin synthesis and conversion of vitamin K1 epoxide to vitamin K1 in rats by 50 and 57%, respectively. Dietary administration of phenindione (4 mg/kg per day) inhibits aortic atherosclerosis or intracardial thrombosis in rat models of diet-induced atherosclerosis or intravascular thrombosis, respectively.

使用Oral anticoagulant (indanedione).

調製方法

純化方法Crystallise the dione from EtOH (m 156o) or CHCl3 (m 148-150o). [Beilstein 7 H 808, 7 III 4100, 7 IV 2570.]

サプライヤー77 社

北京华美互利生物化工010-56205725 · [email protected]
梯希爱(上海)化成工业发展有限公司021-67121386 · [email protected]
上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
艾吉析科技(上海)有限公司17717235263 · [email protected]
成都彼样生物科技有限公司18108052721 · [email protected]

関連反応

1 件

化合物ノート

読み込み中…